Email this article 
Flow cytometry in the diagnosis of plasma cell tumors and assessment of minimal residual disease
- Authors: Grivtsova L.Y.1, Mushkarina T.Y.1, Lunin V.V.2, Zeynalova P.A.3
-
Affiliations:
- A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
- Р.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
- Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
- Issue: Vol 16, No 3 (2021)
- Pages: 16-25
- Section: DIAGNOSIS AND TREATMENT OF MULTIPLE MYELO
- Published: 09.09.2021
- URL: https://oncohematology.abvpress.ru/ongm/article/view/483
- DOI: https://doi.org/10.17650/1818-8346-2021-16-3-16-25
- ID: 483
Cite item
Full Text
Abstract
The article considers the features and possibilities of flow cytometric diagnostics of plasma cell neoplasms, taking into account the classification of lymphoid and hematopoietic tissue tumors of the World Health Organization, revision of 2017 and the NCCN clinical recommendations, 2021. Standardized flow cytometric protocols (the Euro-Flow conception) and algorithms for both the diagnosis of plasma cell tumors and the detection of minimal residual disease in plasma cell myeloma are described.
About the authors
L. Yu. Grivtsova
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Author for correspondence.
Email: grivtsova@mail.ru
ORCID iD: 0000-0001-9103-9688
Lyudmila Yu. Grivtsova
10 Marshala Zhukova St., Obninsk 249031
Russian FederationT. Yu. Mushkarina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0002-1266-1792
10 Marshala Zhukova St., Obninsk 249031
Russian FederationV. V. Lunin
Р.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0001-8689-1227
2 nd Botkinskiy Proezd, Moscow 125284
Russian FederationP. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0003-1564-424X
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationReferences
- Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of tumors of haematopoietic and lemphoid tissues (revised 4th edn). Lyon: JARC, 2017.
- NCCN Clinical Practice Guidelines in Oncology, Version 3.2021.
- Grivtsova L.Yu., Lunin V.V., Semenova A.A. et al. Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches. Oncohematology 2020;15(1):40–50. (In Russ.). doi: 10.17650/1818-83462020-15-1-40-50.
- Reid S., Yang S., Brown R. et al. Characterization and relevance of CD138 negative plasma cells in plasma cell myeloma. Int J Lab Hematol 2010;32(6 Pt 1):190–6. doi: 10.1111/j.1751-553X.2010.01222.x.
- Rawstron A.C., Davies F.E., DasGupta R. et al. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100(9):3095–100. doi: 10.1182/blood-2001-12-0297.
- Rawstron A.C., Orfao A., Beksac M. et al. Report of the European myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93(3):431–8. doi: 10.3324/haematol.11080.
- Van Dongen J.J., Lhermitte L., Böttcher S. et al. Euro-Flow Consortium (EU-FP6, LSHB-CT-2006-018708). Euro-Flow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26(9):1908–75. doi: 10.1038/leu.2012.120.
- Perez-Andres M., Paiva B., Nieto W.G., et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010;78(1):47–60. doi: 10.1002/cyto.b.20547.
- Paiva B., van Dongen J.J., Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015;125:3059–68. doi: 10.1182/blood-2014-11-568907.
- Mateo G., Montalbán M.A., Vidriales M.B. et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/ GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26(16):2737–44. doi: 10.1200/JCO.2007.15.4120.
- Flores-Montero J., Sanoja-Flores L., Paiva B. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31(10): 2094–103. doi: 10.1038/leu.2017.29.
- Flores-Montero J., de Tute R., Paiva B. et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016;90(1):61–72. doi: 10.1002/cyto.b.21265.
Supplementary files
